期刊文献+

Flt3L及CCL5对prime/boost免疫策略中抗原特异性免疫应答的增强及抗肿瘤作用

Immunostimulatory and antitumor effect of Flt3L and CCL5 on DNA vaccine in DNA prime/protein boost strategy
下载PDF
导出
摘要 目的:研究Flt3L与CCL5作为联合佐剂在prime/boost免疫策略中对HBc抗原特异性免疫应答的增强及抗肿瘤作用。方法:将两种细胞因子质粒与携带HBc抗原的DNA疫苗经肌内注射法共免疫小鼠,免疫3次后再用原核表达的HBc颗粒蛋白或HBcDNA疫苗加强,观察对稳定表达HBcAg的小鼠黑色素瘤细胞(B16-HBc)的生长抑制作用;并分别采用MTT法检测荷瘤小鼠脾淋巴细胞增殖、流式细胞术检测脾CD8+T淋巴细胞中IFN-γ表达、ELISA法检测脾淋巴细胞培养上清IL-2、IL-4含量及乳酸脱氢酶(LDH)释放法检测特异性CTL杀伤活性。结果:与对照组相比,佐剂联合DNA疫苗免疫经蛋白加强组(DDP/Adj)显著抑制肿瘤生长;佐剂联合DNA疫苗免疫组(DDD/Adj)及DDP/Adj组均可促进特异性淋巴细胞增殖反应(P<0.05),且DDP/Adj高于DDD/Adj组(P<0.05);DDD/Adj及DDP/Adj组小鼠脾脏CD8+T淋巴细胞中IFN-γ表达、IL-2表达水平及CTL杀靶活性均高于对照组(P<0.01或P<0.05),IL-4表达水平在各组无显著区别(P>0.05)。结论:在prime/boost免疫策略中,采用Flt3L与CCL5两种细胞因子联合应用可显著促进荷瘤小鼠产生抗原特异性免疫应答及抗肿瘤作用。 AIM:To investigate the immune enhancment and antitumor effect of the recombinant plasmids pFlt3L and pCCL5 in DNA prime/protein boost regimens.METHODS:The mice were coimmunized with HBcAg DNA vaccine and the two cytokines DNA constructs by intramuscular injection for three times at an interval of 2 weeks.Then the mice were boosted with HBc particle proteins or DNA vaccines,respectively.The immune efficacy was evaluated by tumor growth curve.To further investigate the mechanism of inhibiting tumor growth,lymphocytes proliferation response and the number of IFN-γ-producing cells in splenocytes were measured by MTT or flow cytometry,respectively.The levels of IL-2 and IL-4 in supernatant of spleno-lymphocyte cultures were measured by ELISA.The CTL activity of spleno-lymphocyte was detected with LDH release assay.RESULTS:Compared with negative control,DDP/Adj group significantly inhibit tumor growth;splenocytes proliferation response and the numbers of IFN-γ-producing cells in DDD/Adj group and DDP/Adj group were significantly higher(P〈0.05 or P〈0.01).The levels of IL-2 in supernatant of spleno-lymphocyte cultures in DDD/Adj group and DDP/Adj group were also markedly higher than that of negative control(P〈0.05);but the levels of IL-4 were no differences in all groups(P〉0.05).The CTL activities in group of DDS/Adj and DDD/Adj were stronger than that of other groups(P〈0.01 or P〈0.05).While,the CTL killing activity in DDS/Adj group was over that of DDD/Adj(P〈0.01 or P〈0.05).CONCLUSION:The significant Th1 response and specific CTL against B16-HBc tumor cells are elicited by the combination of Flt3L and CCL5 in the DNA prime/protein boost strategy.
出处 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2008年第10期982-985,共4页 Chinese Journal of Cellular and Molecular Immunology
基金 河北省科技支撑资助项目(06276102D-30)
关键词 DNA疫苗 Flt3L/CCL5/佐剂 小鼠 抗原特异性免疫应答 prime/boost策略 DNA vaccines Flt3L/CCL5/adjuvant mouse Ag-specific immune response prime/boost strategy
  • 相关文献

参考文献11

  • 1Sumida SM, McKay PF, Truitt DM, et al. Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines[J]. J Clin Invest, 2004, 114(9) : 1334 -1342.
  • 2王良华,熊文,邹红岩.Flt3配体对培养的树突状细胞免疫表型影响的研究[J].现代检验医学杂志,2004,19(4):7-8. 被引量:1
  • 3Brasel K, De Smedt T, Smith JL, et al. Generation of murine dendritic cells from flt3-1igand-supplemented bone marrow cultures[J].Blood, 2000, 96(9): 3029-3039.
  • 4Ma K, Xu W, Shao XN, et al. Coimmunization with RANTES plasmid polarized Thl immune response against hepatitis B vires envelope via recruitment of dendritic cells [ J ]. Antiviral Research, 2007, 76 (2) : 140- 149.
  • 5Palmowski MJ, Choi Ed M, Hermans IF, et al. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols[J].J Immunol, 2002, 168(9) : 4391 -4398.
  • 6Song S, Wang Y, Zhang Y, et al. Augmented induction of CD8^+ cytotoxic T-cell response and antitumor effect by DCs pulsed with viruslike particles packaging with CpG[J].Cancer Letters, 2007, 256:90 - 100.
  • 7Michele A, David K, Weiner B. Developing DNA vaccines that call to dendritic cells[J]. J Clin Investig, 2004, 114(9) : 1241 -1244.
  • 8Matsumura N, Mandai M, Hamanishi J, et al. Immunostimulatory effect of Fms-like tyrosine kinase 3 ligand on peripheral monocyte-derived dendritic cells and natural killer cells: utilization for ovarian cancer treatment[J].Oncol Rep, 2008, 19(2) : 505 -515.
  • 9Inoue H, Iga M, Xin M, et al. TARC and RANTES enhance antitumor immunity induced by the GM-CSF-transduced tumor vaccine in a mouse tumor model [J].Cancer Immunol Immunother, 2008, 57 (19) : 1399 -1411.
  • 10Dunn GP, Koebel CM, Schreiber RD.Interferons, immunity and cancer immunoediting[ J]. Tumor Immunol, 2006, 6( 11 ) : 836 - 848.

二级参考文献7

  • 1Jacques B,Steinmen R M. Dendritric cells and the control of immunity[J]. Nature,1998;392(6673) :245.
  • 2Lotze M T, Shurin M, Davis I, et al. Dendritic cells based therapy of cancer[J]. Adv Exp Med Biol, 1997 ; 417(3) : 551.
  • 3Schuler G,Steinman R M. Dendritic cells as adjuvants for immune-mediated resistance to tumors [J]. J Exp Med,1997 ; 186 (8) : 1183.
  • 4Hart D N J. Dendritic cells: unique leukocyte populations which control the primary immune response[J]. Blood, 1997 ;90(9) :3245.
  • 5Rosenzwajg M,Camus S,et al. The influence of interleukin-4,IL-13 and Flt3 ligand on human dendritic cell differentiation from cord blood CD34+ progenitor cells[J]. Exp Hematol, 1998;26(1) :63.
  • 6郑文婕.早期造血生长因子FLT3配体研究进展[J].国外医学(输血及血液学分册),1998,21(1):16-20. 被引量:1
  • 7沈丽琴.干细胞因子和F1t3配体的造血生物学功能研究进展[J].国外医学(输血及血液学分册),1999,22(4):219-222. 被引量:2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部